New sensor aims to cut hospital visits after heart valve fix
NCT ID NCT07442903
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a small implantable sensor that monitors pressure in the lung artery for patients with severe tricuspid regurgitation and heart failure. The sensor is placed before a minimally invasive valve repair, and pressure readings are tracked for a year. The goal is to see if early detection of pressure changes can prevent hospitalizations. About 45 participants will be enrolled at a single center in Germany.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cordella PA Sensor System (implantable device)
- What this could lead to
- If successful, this could lead to better heart failure management after tricuspid valve repair, potentially reducing hospital stays and improving quality of life.
- What could go wrong
- This is a small pilot study (45 people) testing feasibility, not effectiveness. The device is new for right-sided heart failure, and results may not apply broadly. Risks include complications from sensor implantation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH SEVERE TRICUSPID REGURGITATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
LMU Klinikum
NOT_YET_RECRUITINGMunich, Germany
-
LMU Munich
RECRUITINGMünchen, Germany